Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...

In FCS, mutations in the lipoprotein lipase gene lead to an accumulation of chylomicrons in plasma resulting in severe hypertriglyceridemia.

Impacting an estimated 1 to 10 per million people, familial chylomicronemia syndrome is a rare form of severe hypertriglyceridemia that prevents the body from breaking down and removing ...

Arrowhead Pharmaceuticals said Friday that the Food and Drug Administration accepted the company's new drug application for its treatment of familial chylomicronemia syndrome, a severe and rare ...

Familial chylomicronemia syndrome ... as a treatment for other diseases on that spectrum, including severe hypertriglyceridemia and mixed hyperlipidemia. Top investment firms expect non-US ...